Vaccinex Valuation
| VCNX Stock | USD 3.60 0.11 2.96% |
At this time, the company appears to be undervalued. Vaccinex has a current Real Value of $4.34 per share. The regular price of the company is $3.6. Our model measures the value of Vaccinex from inspecting the company fundamentals such as Return On Equity of -7.59, shares owned by insiders of 9.36 %, and Current Valuation of 8.32 M as well as reviewing its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Vaccinex's valuation include:
Price Book 7.3409 | Enterprise Value 8.3 M | Enterprise Value Ebitda (0.72) | Price Sales 27.0926 | Trailing PE 0.5 |
Undervalued
Today
Please note that Vaccinex's price fluctuation is very risky at this time. Calculation of the real value of Vaccinex is based on 3 months time horizon. Increasing Vaccinex's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Vaccinex is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Vaccinex Stock. However, Vaccinex's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 3.6 | Real 4.34 | Target 7.0 | Hype 3.73 | Naive 3.29 |
The intrinsic value of Vaccinex's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Vaccinex's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Vaccinex helps investors to forecast how Vaccinex stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Vaccinex more accurately as focusing exclusively on Vaccinex's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Vaccinex's intrinsic value based on its ongoing forecasts of Vaccinex's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Vaccinex's closest peers.
Vaccinex Cash |
|
Vaccinex Valuation Trend
Analysing the historical paterns of Vaccinex's enterprise value and its market capitalization is a good way to estimate and gauge the value of Vaccinex over time and is usually enough for investors to make rational market timing decisions.
Vaccinex Total Value Analysis
Vaccinex is at this time estimated to have valuation of 8.32 M with market capitalization of 9.64 M, debt of 247 K, and cash on hands of 11.4 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Vaccinex fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
8.32 M | 9.64 M | 247 K | 11.4 M |
Vaccinex Investor Information
About 49.0% of the company outstanding shares are owned by institutional investors. The company recorded earning per share (EPS) of 7.42. Vaccinex had not issued any dividends in recent years. The entity had 1:14 split on the 20th of February 2024. Based on the key measurements obtained from Vaccinex's financial statements, Vaccinex may be sliding down financialy. It has an above-average odds of going through some form of financial crisis next quarter.Vaccinex Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Vaccinex has an asset utilization ratio of 15.7 percent. This suggests that the Company is making $0.16 for each dollar of assets. An increasing asset utilization means that Vaccinex is more efficient with each dollar of assets it utilizes for everyday operations.Vaccinex Ownership Allocation
30% of Vaccinex outstanding shares are owned by institutional holders. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change.Vaccinex Profitability Analysis
The company reported the previous year's revenue of 570 K. Net Loss for the year was (20.25 M) with loss before overhead, payroll, taxes, and interest of (13.7 M).About Vaccinex Valuation
Our relative valuation model uses a comparative analysis of Vaccinex. We calculate exposure to Vaccinex's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Vaccinex's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -16 M | -15.2 M | |
| Pretax Profit Margin | (35.53) | (37.30) | |
| Operating Profit Margin | (40.15) | (42.16) | |
| Net Loss | (35.53) | (37.30) | |
| Gross Profit Margin | (28.08) | (26.67) |
Vaccinex Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 463.6 K |
Vaccinex Current Valuation Indicators
Valuation refers to the process of determining the present value of Vaccinex and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Vaccinex we look at many different elements of the entity such as Vaccinex's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Vaccinex, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Vaccinex's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Vaccinex's worth.Additional Tools for Vaccinex Stock Analysis
When running Vaccinex's price analysis, check to measure Vaccinex's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vaccinex is operating at the current time. Most of Vaccinex's value examination focuses on studying past and present price action to predict the probability of Vaccinex's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vaccinex's price. Additionally, you may evaluate how the addition of Vaccinex to your portfolios can decrease your overall portfolio volatility.